PF-07926307

PF-07926307 is an investigational monovalent pneumococcal conjugate vaccine (PCV) candidate developed by Pfizer, specifically engineered to target *Streptococcus pneumoniae* serotype 3. Although serotype 3 is included in existing multivalent vaccines such as Prevnar 13 and Prevnar 20, it remains a disproportionate cause of invasive pneumococcal disease due to its thick polysaccharide capsule, which often results in lower vaccine-induced antibody effectiveness compared to other serotypes. PF-07926307 utilizes Pfizer's proprietary conjugation technology to link the serotype 3 capsular polysaccharide to a CRM197 carrier protein, a non-toxic mutant of diphtheria toxin, to induce a T-cell dependent immune response and enhance immunological memory. The vaccine is currently being evaluated in clinical trials to determine if a specialized monovalent formulation can provide superior protection against serotype 3, potentially serving as a booster or a component of future higher-valency vaccines.

Other names

monovalent pneumococcal conjugate vaccine candidatemonovalent PCVmonovalent serotype 3 pneumococcal conjugate vaccine